

Aubagne, July 21, 2022

Information on Document Availability

The report on the first half 2022 results of Sartorius Stedim Biotech Group (Paris: DIM) is now available at: <https://www.sartorius.com/en/company/investor-relations/sartorius-stedim-biotech-sa-investor-relations>

It contains the following information:

- Business development for the period of January to June 2022 as well as the 2022 full year forecast for the Sartorius Stedim Biotech Group
- Consolidated financial statements for the period ended June 30, 2022

A profile of Sartorius Stedim Biotech

Sartorius Stedim Biotech is a leading international partner of the biopharmaceutical industry. As a total solutions provider, the company helps its customers to manufacture biotech medications safely, rapidly and economically. Headquartered in Aubagne, France, Sartorius Stedim Biotech is quoted on the Eurolist of Euronext Paris. With its own manufacturing and R&D sites in Europe, North America and Asia and an international network of sales companies, Sartorius Stedim Biotech has a global reach. The Group has been annually growing by double digits on average and has been regularly expanding its portfolio by acquisitions of complementary technologies. In 2021, the company employed more than 10,400 people, and earned sales revenue of around 2.89 billion euros.

Contact

Petra Müller

Head of Investor Relations

+49 (0)551.308.6035

petra.mueller2@sartorius.com